Overview

First-in-human Single and Multiple Dose Trial of ATR-258

Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
This is a single-site, randomized, double-blinded, placebo-controlled, First-in-Human trial, conducted in 3 parts.
Phase:
Phase 1
Details
Lead Sponsor:
Atrogi AB
Collaborators:
CRS Clinical Research Services
Key2Compliance